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1. Introduction 
Transmissible spongiform encephalopathies (TSE) are transmissible neurodegenerative diseases characterised by long incubation periods and 
characteristic pathology which includes vacuolar spongiform changes, apoptotic neuronal loss and astrocytic proliferation in the central nervous 
system (CNS). A diagnostic feature of these invariably fatal diseases is the presence of a protease resistant isoform (PrPSc) of the host-encoded 
membrane glycoprotein PrP, of which the protease sensitive isoform (PrPc) is necessary for disease susceptibility. Schwann cells are known to 
express PrP when associated with co-expressing peripheral nervous system axons and have also been shown to replicate and propagate TSE agent 
in culture. 
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Figure 3. Box-and-whisker diagram showing incubation period distribution following transmission of mouse-adapted Scrapie strains 139A (a, c, e) and ME7 (b, d, 
f) via intracerebral (a, b), oral (c, d) and intraperitoneal (e, f) routes.  Animals were grouped following post-mortem genotype confirmation, ANOVA revealed no 
significant differences between P0-Cre PrP
fl/fl and control groups: , statistical outliers; ,  group mean incubation period. 
6. Conclusion 
Removal of PrP expression in Schwann cells has no effect on TSE neuroinvasion of the two strains studied. We can therefore 
discount Schwann cells as a viable therapeutic target during the long incubation period between infection and clinical 
presentation. This study has revealed some very interesting biochemical and cell biological properties of PrP. The results from 
this study question what role PrP and its glycosylation status may play in disease. These results also offer insights into possible 
roles for PrP in glial / axonal interaction and cell-cell signalling. 
2. Objectives 
To test the hypothesis that Schwann cells are involved in TSE neuroinvasion, a line of transgenic mice were produced using Cre / LoxP technology 
in which PrP expression is removed from Schwann cells. We have infected these mice with TSE agents via various routes to determine the 
difference in incubation period and CNS pathology when compared to wild type mice. 
3. Methods 
By breeding mice (P0-Cre) expressing Cre under the control of the peripheral myelin Protein Zero (MPZ or P0) promoter (gift from M. Laura Feltri, 
Milan) and mice possessing LoxP sites flanking the PrP gene (PrPfl/fl), we have generated mice expressing PrP normally, except where P0 is 
expressed, i.e. myelinating Schwann cells. Mice were challenged with TSE agents 139A and ME7 intracerebrally (i.c.), orally and intraperitoneally 
(i.p.). Mice were clinically scored for signs of disease and analysed for terminal pathology. Disease incubation period, vacuolation in specific brain 
areas and presence of Proteinase K resistant PrP were analyzed as indicators of TSE disease. 
5. Discussion 
Characterisation of these mice show that PrP is effectively excised, resulting in a 90 % reduction in PrPc expression in axonal lengths of peripheral 
nerves. This finding is particularly interesting as no differences have been observed in disease susceptibility or ability to traffic the infectious agent 
to the CNS in these mice. No alteration was seen in either incubation period or end pathology via agents 139A and ME7 after i.c., oral and i.p. 
challenges.  These results suggest that TSE neuroinvasion may occur via peripheral neurons alone with no involvement of peripheral glia despite 
their contribution to overall PrP expression in peripheral neurons. Also peripheral PrP glycosylation is not required for neuroinvasion and has no 
impact on strain specific properties such as the final targeting of CNS vacuolation and deposition of PrPSc. 
4. Results 
Figure 4. Vacuolar pathology was assessed following transmission of mouse-adapted Scrapie strains 139A (a, c, e) and ME7 (b, d, f) via intracerebral (a, b), oral 
(c, d) and intraperitoneal (e, f) routes.  Brains were scored  on a scale of 0—5 in nine grey matter areas and 0–3 in three white matter areas, animals were 
grouped following post-mortem confirmation of genotype and mean scores calculated to produce lesion profiles (error bars representing ±SEM). Brain scoring 
areas: 1, dorsal medulla; 2, cerebellar cortex; 3, superior colliculus; 4, hypothalamus; 5. medial thalamus; 6, hippocampus; 7, septum; 8, cerebral cortex; 9, 
forebrain cerebral cortex; 10, cerebellar white matter; 11, midbrain white matter; 12, cerebral peduncle. , P0-Cre; , PrP
fl/fl; p, wild type; , P0-Cre PrP
fl/fl. 
Figure 2. a, Western analysis of PrPc expression in brain and sciatic nerve of P0-Cre PrP
fl/fl (lanes marked *) , P0-Cre, wild-
type and PrPfl/fl mice as detected by monoclonal antibody 7A12. Approximate protein size markers in kilodaltons (kDa).  
b, Densitometric analysis of PrPc expression via Kodak 1D™ software showing reduction in PrPc expression between sciatic 
nerve from wild type and P0-Cre PrP
fl/fl compound transgenic mice. 
Figure 1. PrPc (white) detected by fluorescence immunocytochemistry using monoclonal antibodies 7A12 and 8H4 (gift from Man 
Sun Sy, Cleveland). Sciatic nerve cross-section samples: a, wild type; b, P0-Cre PrP
fl/fl and c, PrP0/0. Yellow arrows highlight 
strong PrP staining in myelin ring structures in wild type mice, red and green arrows show residual axonal and periaxonal 
staining respectively following conditional knockout of PrP expression from myelinating Schwann cells in P0-Cre PrP
fl/fl compound 
transgenic mice. Fluorescence detection level was gated using PrP knockout mice. 
a. b. c. 
